Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.
about
Treatment of Helicobacter pylori infection 2017.Antibiotic resistance and gyrA mutation affect the efficacy of 10-day sitafloxacin-metronidazole-esomeprazole therapy for Helicobacter pylori in penicillin allergic patients.World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.Resistance mechanisms of Helicobacter pylori and its dual target precise therapy.Current Status of the Third-Line Helicobacter pylori Eradication.
P2860
Rifabutin-based 10-day and 14-day triple therapy as a third-line and fourth-line regimen for Helicobacter pylori eradication: A pilot study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@en
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@nl
type
label
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@en
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@nl
prefLabel
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@en
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@nl
P2093
P2860
P50
P356
P1476
Rifabutin-based 10-day and 14- ...... ri eradication: A pilot study.
@en
P2093
Hidekazu Suzuki
Hideki Mori
Kenro Hirata
Misako Matsushita
Sawako Miyoshi
Seiichiro Fukuhara
Takashi Seino
Tatsuhiro Masaoka
Toshihiro Nishizawa
P2860
P304
P356
10.1177/2050640615618043
P577
2015-11-13T00:00:00Z